
    
      This is an open label Phase II trial using pemetrexed as second-line treatment in patients
      with advanced pancreatic cancer progressing within six months of prior gemcitabine-based
      therapy. Subjects will receive pemetrexed 500 mg/m2 IV every 21 days until disease
      progression or unacceptable toxicity.
    
  